1Tumour hypoxia in clinical oncology: imaging, therapeutic strategies, and translational challenges.2027 · Europe PMC
2Immunoscore and beyond: evolution and clinical integration of immune contexture-based biomarkers across solid tumours.2026 · Europe PMC
3Tumour GDF-15 Expression and Clinical Outcomes in Intermediate-Risk Metastatic Clear-Cell Renal Cell Carcinoma Treated with Second-Line Nivolumab.2026 · Europe PMC
4Role of Rab4A in the enhancement of cancer cell invasion induced by plasma samples collected during radiotherapy in patients with triple-negative breast cancer.2026 · Europe PMC
5Antimicrobial Peptides of the Skin: Roles in Skin Cancer and Clinical Applications.2026 · Europe PMC
6Exercise and Childhood Cancer: From Science to Life "The 3rd Pediatric Exercise Oncology Congress Meets FORTEe".2026 · Europe PMC
8Implications of ADP-Ribosylation Factor-Like Protein 4C (ARL4C) in Human Neoplasia With Special Emphasis on Ameloblastoma: A Scoping Review.2026 · Europe PMC
10Sister Mary Joseph nodule revealing an ovarian carcinoma: a case report and review of the literature.2026 · Europe PMC
12Matrine induces ferroptosis and suppresses colorectal cancer through targeting the STAT3/SLC7A11 pathway.2026 · Europe PMC
13Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience.2026 · Europe PMC
14Deep learning for H&E-based meningioma molecular classification and outcome prediction: a retrospective cohort study.2026 · Europe PMC
15MNAT1 in gastrointestinal cancers: mechanistic insights and therapeutic strategies-a narrative review.2026 · Europe PMC
16Based on Raman spectroscopy and clinical laboratory tests: Developing a fusion model to predict neoadjuvant therapy response in breast cancer.2026 · Europe PMC
17Hypofractionated chemoradiotherapy for non-small-cell lung cancer in a real-world setting: a single-centre experience.2026 · Europe PMC
18Residual disease in HER2-positive early breast cancer: are we escalating the RIGHT patients to T-DM1 or T-DXd?2026 · Europe PMC
19Lung cancer multidisciplinary care status and evidence-practice gap: a scoping review protocol.2026 · Europe PMC
20Recombinant human erythropoietin therapy in patients with cancer: efficacy, risks and the controversy of EpoR expression.2026 · Europe PMC
21TET1-mediated DNA demethylation and transcription activation of MRPS17 induces lung adenocarcinoma through PI3K-AKT-mTOR pathway.2026 · Europe PMC
22Visualization-driven digital technologies in oncology: current applications, technological advances, and future directions.2026 · Europe PMC
23Cardiac Substructure Dose Quantification and Optimization in Left-Sided Lung Cancer Radiotherapy.2026 · Europe PMC
24The microbiome–nitric oxide axis in cancer immunotherapy: a targeted qualitative systematic review of mechanistic and translational evidence2026 · Europe PMC
25Refractory Hypoglycemia in a Woman With Cirrhosis and a Large Pelvic Mass: A Case Report.2026 · Europe PMC
26Toronto Staging Guidelines for Wilms Tumour: The Meeting Point Between Clinicians and Epidemiologists-Results of the BENCHISTA-ITA Project.2026 · Europe PMC
27Clinical Relevance of Post-Treatment Circulating Tumor DNA Detection in Early Breast Cancer Using a Tissue-Free Epigenomic Assay: A 2-Year Landmark Analysis.2026 · Europe PMC
28FASTINA - protocol for a randomised feasibility trial of time-restricted eating to improve response to multiple myeloma therapy.2026 · Europe PMC
29Atypical Carcinoid Tumor Metastatic to the Parotid Gland: A Case Report and Review of the Literature.2026 · Europe PMC
30Prospective evaluation of radical surgery for adenocarcinoma of oesophagogastric junction: real-world insights from the CLAEG study.2026 · Europe PMC
31Efficacy of circulating tumour DNA in guiding postoperative adjuvant chemotherapy for resectable colorectal cancer: A meta-analysis based on cohort studies.2026 · Europe PMC
32Genome Profiling of Actionable Cancer Targets (NYU LG-PACT) for Clinical Patient Molecular Diagnostics and Treatment2026 · Europe PMC
34Neoantigen cancer vaccines in the mRNA Era: antigen selection, platform engineering, and clinical translation.2026 · Europe PMC
35Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.2026 · Europe PMC
36Targeted ALK inhibition achieving tumour control in metastatic melanoma: a case report.2026 · Europe PMC
37Case Series of Intracranial Central Primitive Neuroectodermal Tumor in Two Adults Treated With Craniospinal Irradiation.2026 · Europe PMC
38Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial.2026 · Europe PMC
40Thiamine deficiency in cancer patients at initial admission to a palliative care unit: a single-centre cross-sectional study.2026 · Europe PMC
41Prognostic markers, quality of life (QoL) and value of health (V-He) in advanced biliary cancers (ABC) treated with second-line active symptom control (ASC) alone or ASC with oxaliplatin-5-FU chemotherapy (ASC + FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 clinical trial.2026 · Europe PMC
42High precision segmentation of glioma and surroundings - a feasibility study using multiparametric MRI and deep learning.2026 · Europe PMC
43A Multimodal Framework to Assess Patient-Derived Colon Tumor Organoid-Immune Cell Co-cultures.2026 · Europe PMC
44Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms.2026 · Europe PMC
48Emerging and Re-Emerging Viral Pathogens in Oncolytic Virotherapy: A Comprehensive Review.2026 · Europe PMC
50Personalized neoantigen mRNA vaccines for pancreatic cancer: the role of lipid nanoparticle delivery systems.2026 · Europe PMC
51Explainable Dual-Task Deep Learning Model for Recurrence Prediction and Dose-Sensitive Region Identification in Head and Neck Cancer Radiation Therapy.2026 · Europe PMC
52Early tumour size changes from neoadjuvant chemotherapy as a predictor of pathologic response in breast cancer.2026 · Europe PMC
53Cyclooxygenase-2 selective inhibitors in cancer prevention and therapy: inflammopharmacological basis and translational prospects.2026 · Europe PMC
54Glycolytic reprogramming in cancer: tumour cell metabolism, immune modulation, and therapeutic opportunities.2026 · Europe PMC
56Neoadjuvant therapy and translational biomarkers for metastatic risk in early breast cancer.2026 · Europe PMC
57Prognostic value of existing scoring systems for early mortality in phase I immunotherapy trials: a head-to-head real-world cohort study.2026 · Europe PMC
58Quantitative magnetic resonance imaging for accurate delineation of radiotherapy: a narrative review.2026 · Europe PMC
60Leveraging Interradiomic Feature Relationships for Enhanced Prediction of Distant Metastasis and Characterization of Heterogeneity in Head and Neck Cancer.2026 · Europe PMC